Yuta Yoshino1, Shinichiro Ochi1, Kiyohiro Yamazaki1, Shunsuke Nakata1, Jun-Ichi Iga2, Shu-Ichi Ueno1. 1. Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. 2. Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. igajunichi@hotmail.com.
Abstract
BACKGROUND: Nitric oxide (NO) is a neurotransmitter that may be related to major depressive disorder (MDD) because the selective neuronal NO synthase (NOS) inhibitor, 7-nitroindazole, induces a dose-dependent antidepressant-like effect. NO modulates major neurotransmitters involved in the neurobiology of MDD, such as norepinephrine, serotonin, dopamine, and glutamate. In this study, we investigated the effects of antidepressants as NO modulators in acute and sub-chronic treatments. METHODS: Rats were injected with the SSRI paroxetine (PAR, 10 mg/kg), the SNRI milnacipran (MIL, 30 mg/kg), or the NaSSA mirtazapine (MIR, 10 mg/kg) for acute (1 h) or sub-chronic (3 weeks) treatment prior to analysis of nine brain regions (frontal cortex, temporal cortex, striatum, thalamus, hippocampus, midbrain, pons, cerebellum, and olfactory bulb). The mRNA expression levels of three NOS subtypes (neuronal: nNOS, inducible: iNOS, and endothelial: eNOS) were analyzed using real-time PCR with Taqman probes. RESULTS: Acute MIR treatment significantly increased nNOS mRNA expression in the hippocampus, midbrain, cerebellum and olfactory bulb, and iNOS mRNA expression in the frontal cortex and midbrain. Acute PAR and MIR treatments significantly increased eNOS mRNA expression in most brain regions. Conversely, sub-chronic treatment with all types of antidepressants resulted in significant decreases of eNOS mRNA expression in most brain regions. CONCLUSIONS: Sub-chronic treatment with the three types of antidepressants consistently decreased eNOS mRNA expression levels in the rat brain. These effects may be associated with the involvement of the NO system in the mechanism of action of antidepressants.
BACKGROUND:Nitric oxide (NO) is a neurotransmitter that may be related to major depressive disorder (MDD) because the selective neuronal NO synthase (NOS) inhibitor, 7-nitroindazole, induces a dose-dependent antidepressant-like effect. NO modulates major neurotransmitters involved in the neurobiology of MDD, such as norepinephrine, serotonin, dopamine, and glutamate. In this study, we investigated the effects of antidepressants as NO modulators in acute and sub-chronic treatments. METHODS:Rats were injected with the SSRI paroxetine (PAR, 10 mg/kg), the SNRI milnacipran (MIL, 30 mg/kg), or the NaSSA mirtazapine (MIR, 10 mg/kg) for acute (1 h) or sub-chronic (3 weeks) treatment prior to analysis of nine brain regions (frontal cortex, temporal cortex, striatum, thalamus, hippocampus, midbrain, pons, cerebellum, and olfactory bulb). The mRNA expression levels of three NOS subtypes (neuronal: nNOS, inducible: iNOS, and endothelial: eNOS) were analyzed using real-time PCR with Taqman probes. RESULTS: Acute MIR treatment significantly increased nNOS mRNA expression in the hippocampus, midbrain, cerebellum and olfactory bulb, and iNOS mRNA expression in the frontal cortex and midbrain. Acute PAR and MIR treatments significantly increased eNOS mRNA expression in most brain regions. Conversely, sub-chronic treatment with all types of antidepressants resulted in significant decreases of eNOS mRNA expression in most brain regions. CONCLUSIONS: Sub-chronic treatment with the three types of antidepressants consistently decreased eNOS mRNA expression levels in the rat brain. These effects may be associated with the involvement of the NO system in the mechanism of action of antidepressants.
Authors: Monika Talarowska; Piotr Gałecki; Michael Maes; Agata Orzechowska; Marcelina Chamielec; Grzegorz Bartosz; Edward Kowalczyk Journal: Neurosci Lett Date: 2012-01-17 Impact factor: 3.046
Authors: H Koprowski; Y M Zheng; E Heber-Katz; N Fraser; L Rorke; Z F Fu; C Hanlon; B Dietzschold Journal: Proc Natl Acad Sci U S A Date: 1993-04-01 Impact factor: 11.205
Authors: Wendy E Chrapko; Paul Jurasz; Marek W Radomski; Nathalie Lara; Stephen L Archer; Jean-Michel Le Mellédo Journal: Biol Psychiatry Date: 2004-07-15 Impact factor: 13.382
Authors: Jie Yang; David J Hellerstein; Ying Chen; Patrick J McGrath; Jonathan W Stewart; Bradley S Peterson; Zhishun Wang Journal: Brain Commun Date: 2022-04-15
Authors: Paulina Wigner; Ewelina Synowiec; Piotr Czarny; Michal Bijak; Paweł Jóźwiak; Janusz Szemraj; Piotr Gruca; Mariusz Papp; Tomasz Śliwiński Journal: J Cell Mol Med Date: 2020-04-13 Impact factor: 5.310